Zacks Investment Research upgraded shares of Oxford Biomedica (NASDAQ:OXBDF) from a hold rating to a buy rating in a report issued on Tuesday, July 11th. The firm currently has $0.25 price objective on the stock.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Shares of Oxford Biomedica (NASDAQ:OXBDF) opened at 0.119 on Tuesday. Oxford Biomedica has a 1-year low of $0.04 and a 1-year high of $0.15. The stock’s market cap is $367.00 million.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/07/oxford-biomedica-nasdaqoxbdf-upgraded-to-buy-at-zacks-investment-research-updated-updated-updated.html.

Get a free copy of the Zacks research report on Oxford Biomedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related stocks with our FREE daily email newsletter.